Based on this evidence, Yu et al. aimed to prove that Src is an important downstream regulator of Cx32 in tumor cells and is associated with chemoresistance to doxorubicin, using HCC tissue samples and 54 and HepG2 cell lines, creating HepG2/DOX cell lines resistant to doxorubicin chemotherapy [68]. This evidence concerns the gene SRC and neoplasm.